Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U7 small nuclear 46 pseudogene (RNU7-46P) is a noncoding RNA gene classified as a **pseudogene**: it is a non-functional segment of genomic DNA related to the U7 small nuclear RNA (U7 snRNA) gene family, which normally plays a role in histone pre-mRNA processing[4][6]. However, as a pseudogene, RNU7-46P lacks the necessary sequence and promoter elements required for functional RNA production and is not transcribed into an active molecule[6]. Functional U7 snRNA genes (e.g., RNU7-1) are critical in the maturation of histone mRNAs, but pseudogenes like RNU7-46P are generally considered "genomic fossils"—unexpressed remnants of former genes that have lost their functional role due to mutations or genomic rearrangements[6]. There is no evidence in the scientific literature suggesting that RNU7-46P serves as a therapeutic target, biomarker, or participant in any known disease[6]. Additionally, it is not included in conventional gene or drug target databases as a therapeutically exploitable entity, nor is it involved in drug interactions, mechanisms of action, or safety concerns. Additional Notes: U7 snRNA (the functional gene product) is a small nuclear RNA essential for processing the 3' ends of histone pre-mRNAs, but RNU7-46P is one of several human U7-related pseudogenes lacking function[4][6]. Pseudogenes are abundant in the human genome, and while a few may have regulatory or “ghost” functions, no such role has been described for RNU7-46P[6]. Information on RNU7-46P is limited, and confusion with the functional RNU7-1 gene should be avoided[1][2]. In summary, RNU7-46P is not a functional gene or therapeutic target, but rather a nonfunctional pseudogene related to the U7 snRNA family[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U7 small nuclear 46 pseudogene (RNU7-46P).